Literature DB >> 22002520

EpCAM expression is an indicator of recurrence in basal-like breast cancer.

Ayodeji J Agboola1, E Claire Paish, Emad A Rakha, Desmond G Powe, R Douglas Macmillan, Ian O Ellis, Andrew R Green.   

Abstract

Advances in the understanding of the molecular basis of breast cancer have necessitated a definition of more sensitive and specific indicators of prognosis that are central to the underlying cancer biology and that reflect the complicated and heterogeneous nature of the disease. This study investigates the expression of epithelial cell adhesion molecule (EpCAM) in breast cancer particularly basal-like phenotype group which remains unclear. EpCAM expression was assessed using immunohistochemistry in a large well-characterised series of breast carcinomas prepared as tissue microarrays. Relationships between EpCAM expression with molecular subtypes, clinicopathological variables and patients' outcome were examined. EpCAM expression was associated with higher tumour grade (P < 0.001), larger tumour size (P < 0.001) and basal phenotype (P = 0.03). Importantly, within the basal-like tumours those positive for EpCAM showed a significantly shorter DFI (LR = 7.97, P = 0.005) and MFS (LR 4.01, P = 0.045). EpCAM may play a role in breast cancer progression and its expression is associated with poor patient outcome in basal-like breast cancer, independent of other prognostic factors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22002520     DOI: 10.1007/s10549-011-1813-7

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  12 in total

1.  The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes.

Authors:  Maryam Althobiti; Abir A Muftah; Mohammed A Aleskandarany; Chitra Joseph; Michael S Toss; Andrew Green; Emad Rakha
Journal:  Breast Cancer Res Treat       Date:  2020-06-10       Impact factor: 4.872

Review 2.  Protein biomarkers for subtyping breast cancer and implications for future research.

Authors:  Claudius Mueller; Amanda Haymond; Justin B Davis; Alexa Williams; Virginia Espina
Journal:  Expert Rev Proteomics       Date:  2018-01-03       Impact factor: 3.940

3.  Comparative stemness and differentiation of luminal and basal breast cancer stem cell type under glutamine-deprivation.

Authors:  Heena Jariyal; Chanchal Gupta; Shambhavi Andhale; Sonali Gadge; Akshay Srivastava
Journal:  J Cell Commun Signal       Date:  2021-01-28       Impact factor: 5.782

4.  Overexpression of EpCAM and Trop2 in pituitary adenomas.

Authors:  Xin Chen; Bo Pang; Yu Liang; Shang-Chen Xu; Tao Xin; Hai-Tao Fan; Yan-Bing Yu; Qi Pang
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

5.  The diagnostic, predictive, and prognostic role of serum epithelial cell adhesion molecule (EpCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in breast cancer.

Authors:  S Karabulut; F Tas; D Tastekin; M Karabulut; C T Yasasever; R Ciftci; M Güveli; M Fayda; S Vatansever; M Serilmez; R Disci; A Aydıner
Journal:  Tumour Biol       Date:  2014-06-03

6.  Trop2 is overexpressed in gastric cancer and predicts poor prognosis.

Authors:  Wei Zhao; Huijun Zhu; Shu Zhang; Hongmei Yong; Wei Wang; Yan Zhou; Bing Wang; Jinbo Wen; Zhenning Qiu; Guipeng Ding; Zhenqing Feng; Jin Zhu
Journal:  Oncotarget       Date:  2016-02-02

7.  By inhibiting Ras/Raf/ERK and MMP-9, knockdown of EpCAM inhibits breast cancer cell growth and metastasis.

Authors:  Jiujiao Gao; Xue Liu; Fan Yang; Tingjiao Liu; Qiu Yan; Xuesong Yang
Journal:  Oncotarget       Date:  2015-09-29

8.  Hepatocellular carcinoma: Intratumoral EpCAM-positive cancer stem cell heterogeneity identifies high-risk tumor subtype.

Authors:  Jenny Krause; Johann von Felden; Christian Casar; Thorben W Fründt; Johanna Galaski; Constantin Schmidt; Caroline Jung; Harald Ittrich; Sören A Weidemann; Till Krech; Asmus Heumann; Jun Li; Lutz Fischer; Guido Sauter; Ansgar W Lohse; Henning Wege; Kornelius Schulze
Journal:  BMC Cancer       Date:  2020-11-23       Impact factor: 4.430

9.  The Predictive Role of Serum Levels of Soluble Cell Adhesion Molecules (sCAMs) in the Therapy of Advanced Breast Cancer-A Single-Centre Study.

Authors:  Weronika Bulska-Będkowska; Paulina Czajka-Francuz; Sylwia Jurek-Cisoń; Aleksander J Owczarek; Tomasz Francuz; Jerzy Chudek
Journal:  Medicina (Kaunas)       Date:  2022-01-19       Impact factor: 2.430

10.  EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2(+), basal-like, and HER2 intrinsic subtypes of breast cancer.

Authors:  S D Soysal; S Muenst; T Barbie; T Fleming; F Gao; G Spizzo; D Oertli; C T Viehl; E C Obermann; W E Gillanders
Journal:  Br J Cancer       Date:  2013-03-21       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.